Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Roles of neutrophil/lymphocyte ratio in prognosis and in differentiation of potential beneficiaries in HER2-positive breast cancer with trastuzumab therapy

Fig. 3

DFS outcome among three groups of 843 HER2-positive BC patients. Patients in group 2 showed significantly higher 3-year DFS rate than patients in group 1 or group 3. Patients in the group 1 and group 3 had similar 3-year DFS outcome. Group 1 (without trastuzumab treatment), group 2 (with trastuzumab treatment and low pre-NLR value) and group 3 (with trastuzumab treatment and high pre-NLR value)

Back to article page